Form 4: Tevogen Bio Holdings Inc. Executive Receives Stock Grant

Tevogen Bio Holdings Inc. reports a significant stock grant to CEO Ryan H. Saadi, comprising 1.22 million restricted shares vesting over four years.

Summary

• Ryan H. Saadi, CEO, Director, and 10% owner of Tevogen Bio Holdings Inc., received a grant of 1,220,000 restricted shares of common stock on July 10, 2026.
• This grant is part of the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The restricted shares will vest ratably in four equal annual installments, starting on July 10, 2033.
• Vesting is contingent upon Mr. Saadi remaining in service with the Issuer at the time of each installment.
• Following this transaction, Mr. Saadi beneficially owns 3,705,689 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting long-term executive commitment, but the distant vesting date tempers immediate impact.

Positives

• Significant stock grant awarded to the CEO, indicating a long-term incentive and alignment with company performance.
• The grant of 1,220,000 restricted shares demonstrates confidence in the company's future prospects.
• The vesting schedule over four years, commencing in 2033, suggests a long-term commitment from leadership.
• Mr. Saadi's continued service is a condition for vesting, reinforcing his dedication to the company.

Negatives

• The vesting commencement date of July 10, 2033, is significantly in the future, implying a long wait for the full realization of the grant's value.
• The grant is subject to continued service, meaning the shares could be forfeited if Mr. Saadi leaves the company before vesting.

Risks

• The long vesting period (commencing 2033) introduces a risk that the value of the grant may fluctuate significantly before it vests.
• Continued service is a condition for vesting, meaning any departure from the company prior to July 10, 2033, would result in forfeiture of the unvested portion of the grant.

Future Outlook

The grant of restricted stock with a long vesting period suggests management's long-term commitment and belief in the future value creation of Tevogen Bio Holdings Inc.

Industry Context

StockSavvy.ai notes that long-term incentive grants to key executives are a common practice in the biotechnology sector to align leadership interests with shareholder value and retain talent through extended vesting periods.

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with long-term shareholder value, but the distant vesting means immediate impact on share price is unlikely.
• Employees: May signal stability and long-term vision from leadership.
• Management: Reinforces the commitment of the CEO to the company's future.

Next Steps

• Ryan H. Saadi to remain in service with Tevogen Bio Holdings Inc. to meet vesting conditions.
• Vesting of restricted stock to occur annually in four equal installments starting July 10, 2033.

Key Dates

Keywords

Tevogen Bio Holdings Inc., Ryan H. Saadi, Form 4, Stock Grant, Restricted Stock, Omnibus Incentive Plan, Beneficial Ownership, Executive Compensation, Vesting Schedule, SEC Filing